alogabat (RG7816) / Roche 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
alogabat (RG7816) / Roche
NCT04299464 / 2019-003524-20: A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)

Completed
2
104
Europe, Canada, US
Placebo, RO7017773
Hoffmann-La Roche
Autism Spectrum Disorder (ASD)
05/24
05/24
NCT05630066: Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.

Recruiting
2
56
Europe, US, RoW
60 mg QD Alogabat, 40 mg QD Alogabat, 7 mg QD Alogabat, Part 2 Adult Alogabat High Dose (aged 15-17), Alogabat, Part 2 Optional Cohort
Hoffmann-La Roche
Angelman Syndrome
09/25
09/25

Download Options